Literature DB >> 8306415

Induction of apoptosis in murine tumors by cyclophosphamide.

R E Meyn1, L C Stephens, N R Hunter, L Milas.   

Abstract

Whereas there have been several recent reports of the induction of apoptosis by chemotherapy agents in cell culture systems, much less is known about the role of this mode of cell death in tumors treated in vivo. We therefore quantitated the proportion of apoptotic cells induced as a function of time and dose in two murine tumors treated with cyclophosphamide in vivo. The two tumors were a mammary adenocarcinoma, MCa-4, and an ovarian adenocarcinoma, OCa-1. The percent apoptosis was scored from stained histological sections of the tumors using a system based on the characteristic features of the apoptotic nuclei. The kinetics of apoptosis development were determined over a 5-day period following treatment of the mice with 200 mg/kg. The percent apoptosis peaked between 10-18 h in both tumors and then slowly declined to background levels by 5 days after treatment. The dose responses showed that even much lower doses, 25 mg/kg, could induce significant apoptosis and that the proportion of apoptotic cells plateaued at doses higher than 100 mg/kg. These results are compared and contrasted with our previous reports on apoptosis induction in these same tumors with ionizing radiation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8306415     DOI: 10.1007/BF00686270

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  22 in total

Review 1.  Activation of programmed cell death by anticancer agents: cisplatin as a model system.

Authors:  A Eastman
Journal:  Cancer Cells       Date:  1990 Aug-Sep

2.  Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia.

Authors:  M A Barry; C A Behnke; A Eastman
Journal:  Biochem Pharmacol       Date:  1990-11-15       Impact factor: 5.858

3.  Response of parotid gland organ culture to radiation.

Authors:  L C Stephens; T E Schultheiss; S M Small; K K Ang; L J Peters
Journal:  Radiat Res       Date:  1989-10       Impact factor: 2.841

4.  Radiation-induced interphase death of rat thymocytes is internally programmed (apoptosis).

Authors:  T Yamada; H Ohyama
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1988-01

5.  Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes.

Authors:  K S Sellins; J J Cohen
Journal:  J Immunol       Date:  1987-11-15       Impact factor: 5.422

6.  Glucocorticoid activation of a calcium-dependent endonuclease in thymocyte nuclei leads to cell death.

Authors:  J J Cohen; R C Duke
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

Review 7.  Cell death: the significance of apoptosis.

Authors:  A H Wyllie; J F Kerr; A R Currie
Journal:  Int Rev Cytol       Date:  1980

8.  An electron-microscope study of the mode of cell death induced by cancer-chemotherapeutic agents in populations of proliferating normal and neoplastic cells.

Authors:  J Searle; T A Lawson; P J Abbott; B Harmon; J F Kerr
Journal:  J Pathol       Date:  1975-07       Impact factor: 7.996

9.  Effect of tumor size on S-2-(3-aminopropylamino)ethylphosphorothioic acid and misonidazole alteration of tumor response to cyclophosphamide.

Authors:  L Milas; H Ito; N Hunter
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

10.  Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies.

Authors:  R E Meyn; L C Stephens; K K Ang; N R Hunter; W A Brock; L Milas; L J Peters
Journal:  Int J Radiat Biol       Date:  1993-11       Impact factor: 2.694

View more
  9 in total

1.  Dose-response relationship in cyclophosphamide-treated B-cell lymphoma xenografts monitored with [18F]FDG PET.

Authors:  Lieselot Brepoels; Marijke De Saint-Hubert; Sigrid Stroobants; Gregor Verhoef; Jan Balzarini; Luc Mortelmans; Felix M Mottaghy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-05-12       Impact factor: 9.236

Review 2.  Apoptosis: molecular mechanisms and implications for cancer chemotherapy.

Authors:  H J Guchelaar; A Vermes; I Vermes; C Haanen
Journal:  Pharm World Sci       Date:  1997-06

Review 3.  Optimisation of cyclophosphamide therapy in systemic vasculitis.

Authors:  R Richmond; T W McMillan; R A Luqmani
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 4.  Programmed cell death and radioresistance.

Authors:  R E Meyn; L C Stephens; L Milas
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

5.  Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol.

Authors:  L Milas; N R Hunter; B Kurdoglu; K A Mason; R E Meyn; L C Stephens; L J Peters
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Imaging and dosimetry of 99mTc EC annexin V: preliminary clinical study targeting apoptosis in breast tumors.

Authors:  Hiroaki Kurihara; David J Yang; Massimo Cristofanilli; William D Erwin; Dong-Fang Yu; Saady Kohanim; Richard Mendez; E Edmund Kim
Journal:  Appl Radiat Isot       Date:  2008-01-26       Impact factor: 1.513

7.  Mistiming Death: Modeling the Time-Domain Variability of Tumor Apoptosis and Implications for Molecular Imaging of Cell Death.

Authors:  Seth T Gammon; Brian J Engel; Gregory J Gores; Erik Cressman; David Piwnica-Worms; Steven W Millward
Journal:  Mol Imaging Biol       Date:  2020-10       Impact factor: 3.488

8.  99mTc-HYNIC-Annexin A5 in Oncology: Evaluating Efficacy of Anti-Cancer Therapies.

Authors:  Frédéric L W V J Schaper; Chris P Reutelingsperger
Journal:  Cancers (Basel)       Date:  2013-05-15       Impact factor: 6.639

9.  Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer.

Authors:  C D Archer; M Parton; I E Smith; P A Ellis; J Salter; S Ashley; G Gui; N Sacks; S R Ebbs; W Allum; N Nasiri; M Dowsett
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.